You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Multisensor Fused Track and Discrimination Architecture

    SBC: DECIBEL RESEARCH, INC.            Topic: MDA06T003

    This effort will extend the Phase I design, development, implementation, testing and performance evaluation of an automated prototype Multisensor Attributes and Contextual Information-Aided Track Correlation Algorithm. The proposed algorithm integrates the following modules based modified/enhanced existing stand-alone algorithms: a) A basic Multisensor Data Collection and Feature Extraction Module ...

    STTR Phase II 2007 Department of DefenseMissile Defense Agency
  3. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy

    SBC: APOIMMUNE, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, designed to specifically deliver survivin, a tumor associated antigen (TAA) to professional antigen-presenting cells (APCs) and activate them for the generation of an effective anti-tumor immune respon ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Diagnostic Test for Alzheimer's Disease

    SBC: SCOUT DIAGNOSTICS            Topic: N/A

    DESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stages when therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this proposal is that levels of a novel protein ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Enhancement of the baculovirus expression vector system

    SBC: PARATECHS CORP            Topic: N/A

    DESCRIPTION (provided by applicant): The baculovirus expression vector system (BEVS) is one of the most powerful and versatile eukaryotic expression systems. The BEVS is being used to produce antigens for vaccine development, to manufacture human therapeutics, to develop faster acting biological insecticides, and as a protein expression system for a multitude of research projects. However, a limit ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  9. Hypericum extracts as potential anti-relapse medications in alcoholism

    SBC: NAPROGENIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholism is a complex disease and anti-relapse treatments should recognize this. For example, depression is a frequent precipitant of relapse (1) and is the most common co-morbid psychiatric disorder in alcoholism. An anti-relapse agent with antidepressant properties might therefore be valuable, specifically for this large subpopulation. In this regard, the ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Hypericum extracts as potential anti-relapse medications in alcoholism

    SBC: NAPROGENIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholism is a complex disease and anti-relapse treatments should recognize this. For example, depression is a frequent precipitant of relapse (1) and is the most common co-morbid psychiatric disorder in alcoholism. An anti-relapse agent with antidepressant properties might therefore be valuable, specifically for this large subpopulation. In this regard, the e ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government